Liminatus Pharma, Inc. SEC filings LIMNW
Liminatus Pharma, Inc. has 109 filings in SEC EDGAR's recent list, going back to May 2, 2023. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (material agreement, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Nov 3, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Sep 29, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Listing notice, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 18, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 4, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Other events
|
Jul 30, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Jul 24, 2026 | Jul 20, 2026 |
| DEF 14A | Proxy statement | Jul 13, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Bylaw or fiscal year change
|
Jul 6, 2026 | Jun 29, 2026 |
| PRE 14A | Preliminary proxy statement | Jun 30, 2026 | Jun 29, 2026 |
| S-1 | Registration statement | Jun 24, 2026 | — |
| D | Filing | Jun 18, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Other events
|
Jun 3, 2026 | Jun 3, 2026 |
| 424B3 | Prospectus | Jun 3, 2026 | — |
| 8-K |
Current report
Listing notice
|
May 27, 2026 | May 20, 2026 |
| 8-K |
Current report
Material agreement
|
May 20, 2026 | May 17, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Mar 4, 2026 | Feb 27, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Feb 18, 2026 | Feb 17, 2026 |
| 424B4 | Prospectus | Feb 18, 2026 | — |
| EFFECT | Filing | Feb 13, 2026 | — |
| CORRESP | Letter to the SEC | Feb 11, 2026 | — |
| CORRESP | Letter to the SEC | Feb 11, 2026 | — |
| S-1 | Registration statement | Feb 11, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Feb 9, 2026 | Feb 6, 2026 |
| 8-K |
Current report
Listing notice
|
Jan 26, 2026 | Jan 15, 2026 |
| UPLOAD | Letter from the SEC | Jan 6, 2026 | — |
| DRS | Filing | Dec 31, 2025 | — |
| 8-K |
Current report
Listing notice
|
Nov 25, 2025 | Nov 19, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Oct 6, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Listing notice
|
Aug 25, 2025 | Aug 22, 2025 |
| NT 10-Q | Filing | Aug 15, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 14, 2025 | Aug 14, 2025 |
| 424B3 | Prospectus | Aug 13, 2025 | — |
| EFFECT | Filing | Aug 12, 2025 | — |
| CORRESP | Letter to the SEC | Aug 11, 2025 | — |
| S-1/A | Amended registration statement | Jul 28, 2025 | — |
| CORRESP | Letter to the SEC | Jul 25, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jul 17, 2025 | Jul 16, 2025 |
| 8-K |
Current report
Officer or director change
|
Jul 11, 2025 | Jul 10, 2025 |
| UPLOAD | Letter from the SEC | Jul 3, 2025 | — |
| 8-K |
Current report
Other events
|
Jul 3, 2025 | Jul 2, 2025 |
| S-1 | Registration statement | Jun 24, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 24, 2025 | Jun 24, 2025 |
| 8-K |
Current report
Other events
|
Jun 24, 2025 | Jun 23, 2025 |
| 8-K |
Current report
Listing notice
|
Jun 4, 2025 | May 29, 2025 |
| 10-Q | Quarterly report | Jun 2, 2025 | Mar 31, 2025 |
| 8-K/A |
Amended current report
Acquisition or sale of assets
|
Jun 2, 2025 | Apr 30, 2025 |
| NT 10-Q | Filing | May 15, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
May 6, 2025 | Apr 30, 2025 |
| 8-K12B | Filing | Apr 30, 2025 | Apr 30, 2025 |
| 424B3 | Prospectus | Feb 7, 2025 | — |
| EFFECT | Filing | Feb 6, 2025 | — |
| CORRESP | Letter to the SEC | Feb 4, 2025 | — |
| POS AM | Filing | Jan 27, 2025 | — |
| CORRESP | Letter to the SEC | Jan 27, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2025 | — |
| POS AM | Filing | Jan 16, 2025 | — |
| CORRESP | Letter to the SEC | Jan 15, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 5, 2024 | — |
| POS AM | Filing | Nov 8, 2024 | — |
| 424B3 | Prospectus | Aug 12, 2024 | — |
| EFFECT | Filing | Aug 9, 2024 | — |
| CORRESP | Letter to the SEC | Aug 9, 2024 | — |
| S-4/A | Filing | Aug 9, 2024 | — |
| S-4/A | Filing | Aug 9, 2024 | — |
| CORRESP | Letter to the SEC | Aug 8, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2024 | — |
| S-4/A | Filing | Aug 7, 2024 | — |
| CORRESP | Letter to the SEC | Aug 7, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 5, 2024 | — |
| S-4/A | Filing | Jul 25, 2024 | — |
| CORRESP | Letter to the SEC | Jul 25, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 11, 2024 | — |
| S-4/A | Filing | Jun 14, 2024 | — |
| CORRESP | Letter to the SEC | Jun 14, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2023 | — |
| CORRESP | Letter to the SEC | Nov 8, 2023 | — |
| S-4 | Registration for a merger or exchange | Nov 8, 2023 | — |
| UPLOAD | Letter from the SEC | May 30, 2023 | — |
| DRS | Filing | May 2, 2023 | — |
Showing 83 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LIMN (Nasdaq), LIMNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cerritos, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1971387
- Former names
- Iris Parent Holding Corp. (until Feb 7, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.